SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...
Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...
Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results